New findings may enhance PARP inhibitors therapy in BC

cp418

http://www.sciencedaily.com/releases/2016/01/16011...

New findings may enhance PARP inhibitors therapy in breast cancer

PARP inhibitors, an emerging class of drugs being studied in cancer clinical trials, may be enhanced by combining them with inhibitors targeting an oncogene known as c-MET which is overexpressed in many cancers, new research shows.

JohnSmith

Are PARP inhibitors only approved for ovarian cancer patients that have BRCA mutations?

It's a good idea to expand evaluation of PARP inhibitors for all patients without a BRCA mutation, imo.